Hydroxyamine

Hydroxyamine

SCHEMBL6529639

NO.O=C(O)C1CNCCN1S(=O)(=O)CCCCCOCc1ccccc1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 7/20 0.41
MMP8 P22894 3/20 0.39
MMP12 P39900 3/20 0.39
MMP13 P45452 3/20 0.39
MMP1 P03956 1/20 0.39
MMP7 P09237 1/20 0.39
EPHX2 P34913 2/20 0.38
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP10 P09238 1/20 0.37
TEAD3 Q99594 1/20 0.37
KMT2A Q03164 1/20 0.36
GBA1 P04062 2/20 0.36
UGCG Q16739 2/20 0.36
GBA2 Q9HCG7 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA9 Q16790 2/20 0.36
AGTR2 P50052 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5894483 0.88 MMP8 (0.52) FKBP1AMMP8MMP12MMP13MMP1
Hydroxyamine SCHEMBL5894541 0.85 FKBP1A (0.52) FKBP1AMMP8MMP12MMP13MMP1
Hydroxyamine SCHEMBL5894189 0.76 FKBP1A (0.40) FKBP1AMMP8MMP13MMP1MMP7
Hydroxyamine SCHEMBL6529638 0.72 MMP1 (0.35) FKBP1AMMP13MMP1MMP7MMP2
SCHEMBL22071071 0.67 CA2 (0.49) EPHX2CA1CA2CA4CA9
SCHEMBL7251746 0.67 HTR2C (0.53) KMT2A
SCHEMBL8220722 0.67 HTR2C (0.53) KMT2A
Hydrochloric Acid SCHEMBL28277924 0.66 MGLL (0.47) EPHX2TEAD3GBA1UGCGGBA2
SCHEMBL6598977 0.66 MGLL (0.49) EPHX2TEAD3GBA1UGCGGBA2
SCHEMBL1873560 0.65 SLC6A2 (0.42) KMT2ACA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227997-A1 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction NOE MARK C 2005-10-13 US disclosed
EP-1081137-A1 Selective inhibitors of aggrecanase in osteoarthritis treatment Pfizer Products Inc. (US) 2001-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227997-A1 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction MMP3, MMP1, MMP13 FKBP1A 2344/4885MMP8 28/4885MMP12 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.